Publicaciones › Edema macular diabético y sus tratamientos
One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
Resultado a un año de la inyección intravítrea de Aflibercept en ojos vitrectomizados con edema macular diabético
| Año | 2021 |
|---|---|
| Fuente | Clinical ophthalmology (Auckland, N.Z.) |
| Tipo | article · Journal Article |
| Autores (9) | Thi Ha Chau Tran, Ali Erginay, Stephane Verdun, Eric Fourmaux, Jean-François Le Rouic, Joel Uzzan, Solange Milazzo, Stephanie Baillif, Laurent Kodjikian |
| Posición de Erginay | 2 de 9 |
| Citas | 9 (OpenAlex) |
| Enlaces | DOI 10.2147/opth.s304030 · PubMed 34007150 · OpenAlex · Texto completo en acceso abierto |
| Líneas | Edema macular diabético y sus tratamientos Interfase vitreomacular, agujero macular y miopía alta Retinopatía diabética: clínica, función y progresión Imagen retiniana: OCT, OCT-angiografía y ultra-gran campo |
En pocas palabras
Se estudió la efectividad de la inyección intravítrea de Aflibercept en pacientes con edema macular diabético que habían sido sometidos a vitrectomía. Los resultados mostraron una mejora significativa en la agudeza visual y una reducción en el grosor de la mácula después de un año de tratamiento. Se necesitaron inyecciones frecuentes para lograr esta mejora.
Resumen divulgativo generado automáticamente a partir del resumen original; puede contener imprecisiones.
Resumen original
AIM: To evaluate the efficacy of intravitreal Aflibercept injection (IAI) for vitrectomized eyes with diabetic macular edema (DME) at one year. METHODS: This is a prospective, non-comparative, multicenter observational study including diabetic patients whose HbA1c is < 9%, with visual acuity between 20/400 to 20/40 due to DME, who have undergone vitrectomy since at least 3 months before the first aflibercept injection. Treatment protocol included 5 monthly aflibercept injection followed by a ProReNata regimen during the first year. Visual acuity, OCT findings and number of IAI were assessed at 6 months and one year. RESULTS: Forty-six eyes were included. Indications for vitrectomy were epiretinal membrane (58.7%), intravitreal hemorrhage (26.1%), and vitreomacular traction (8.7%), retinal detachment (4.3%), and other cause (4.3%). Median duration of macular edema was 3 years. Median interval between vitrectomy and first visit was 9 months. Thirty eyes were non-naïve and received previously thermal laser (44.3%), intravitreal injection of triamcinolone (26.7%), of ranibizumab (70%), of dexamethasone implant (36.7%), or bevacizumab (6.7%). Data was available for 35 eyes at 1 year. Visual gain was significant, +6 letters (p <0.001) and central subfield thickness (CST) decreased significantly (-108μm, p < 0.001) at 1 year. Mean number of injections was 9.3 and mean interval injection was 5.8 weeks. CONCLUSION: These results suggest that IAI may be beneficial in vitrectomized eyes with refractory DME which require frequent injections to obtain visual and anatomical improvement. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov, registration Number NCT02874859.